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Abstract Cornelia de Lange syndrome (CdLS) is a rare
multi-system genetic disorder characterised by growth and
developmental delay, distinctive facial dysmorphism, limb
malformations and multiple organ defects. The disease is
caused by mutations in genes responsible for the formation
and regulation of cohesin complex. About half of the cases
result from mutations in the NIPBL gene coding delangin, a
protein regulating the initialisation of cohesion. To date,
approximately 250 point mutations have been identified in
more than 300 CdLS patients worldwide. In the present
study, conducted on a group of 64 unrelated Polish CdLS
patients, 25 various NIPBL sequence variants, including 22
novel point mutations, were detected. Additionally, large
genomic deletions on chromosome 5p13 encompassing the
NIPBL gene locus were detected in two patients with the
most severe CdLS phenotype. Taken together, 42 % of
patients were found to have a deleterious alteration affecting
the NIPBL gene, by and large private ones (89 %). The
review of the types of mutations found so far in Polish
patients, their frequency and correlation with the severity
of the observed phenotype shows that Polish CdLS cases do
not significantly differ from other populations.
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Introduction
Cornelia de Lange syndrome (CdLS; OMIM#122470) is a
rare autosomal dominant multi-system disorder with an
estimated incidence of 1:10,000–1:50,000 live births. Al-
though most of the cases occur sporadically, familial inci-
dence has also been reported (Beck 1976, Russell et al.
2001; Barisic et al. 2008). The phenotype of patients with
CdLS is very characteristic. The major clinical manifesta-
tions include a distinctive facial appearance (synophrys and
high arched eyebrows in particular), prenatal and postnatal
growth retardation, malformations of the extremities, espe-
cially the upper limbs, hirsutism, psychomotor retardation
and a wide range of gastrointestinal problems (Gillis et al.
2004; Kline et al. 2007; Selicorni et al. 2007; Oliver et al.
2010). The severity of each of the aforesaid features differs
significantly between the patients, which has prompted to
define two CdLS subtypes: a mild form and the classical
severe form (Kline et al. 2007; Oliver et al. 2010).
The disorder is referred to as a cohesinopathy, since it is
caused by alterations in genes involved in the proper inter-
action of the cohesin complex, such as NIPBL, PDS5 (cod-
ing cohesion regulators) and SMC1, SMC3, RAD21 (coding
proteins of the core of the cohesin complex) (Krantz et al.
2004; Tonkin et al. 2004; Zhang et al. 2009; Musio et al.
2006; Deardorff et al. 2007; Deardorff et al. 2012a). The
primary function of the cohesin complex is to regulate
chromosome segregation during cell division; however, co-
hesion is also implicated in the regulation of gene expres-
sion and DNA repair (Dorsett and Krantz 2009; Feeney et
al. 2010). Accordingly, deleterious alteration of any of the
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genes coding proteins of the cohesin complex may affect
early stages of prenatal development (Dorsett 2011).
The most common dysfunction of cohesin complex ob-
served in CdLS patients is caused by mutations in the NIPBL
gene, which is located on the chromosome 5p13.2 and consists
of 47 exons. Its protein product is delangin, a 2804 aa human
orthologue of fungal Scc2 and the Drosophila Nipped-B pro-
teins. Delangin is involved in sister chromatid cohesion by
interacting with the cohesin complex. The regulation of cohe-
sin complex attachment to chromatids gives the possibility to
control the expression of a number of genes (Liu et al. 2009;
Bose and Gerton 2010). Homozygous mutations in the NIPBL
gene had never been previously reported, providing further
evidence of its crucial function in embryogenesis. Approxi-
mately 50 % of CdLS patients have a pathogenic mutation in
the NIPBL gene, although the mutation detection rate differs
considerably between various reports, ranging from 26 to 70%
(Borck et al. 2004; Gillis et al. 2004;Miyake et al. 2005; Yan et
al. 2006; Bhuiyan et al. 2006; Schoumans et al. 2007; Selicorni
et al. 2007; Kline et al. 2007; Pié et al. 2010).
To date, approximately 250 different point mutations have
been identified in more than 300 CdLS patients (Leiden Open
Variation Database; LODV: http://grenada.lumc.nl/LOVD2/
CDLS/home.php?select_db0NIPBL). Alterations are local-
ised along the entire coding sequence of the gene and, al-
though some of them were reported in a few unrelated
patients, no obvious hot spot has been found so far (Oliveira
et al. 2010). A correlation between the type of point mutations
and the severity of the phenotype has been observed. Trun-
cating mutations are most commonly identified among
patients with classical CdLS subtype, while missense muta-
tions or small in-frame deletions/duplications more likely
cause milder phenotype (Gillis et al. 2004; Yan et al. 2006;
Pié et al. 2010; Oliveira et al. 2010). Moreover, in a few cases,
a large genomic rearrangement involving the NIPBL gene has
been detected, indicating even higher complexity of the ge-
netic background of the syndrome. Observed genomic alter-
ations were mostly deletions, encompassing one or more of
NIPBL exons; however, also, a few pathogenic duplications
were reported (Bhuiyan et al. 2007; Ratajska et al. 2010;
Oliver et al. 2010; Murray et al. 2012; Pehlivan et al. 2012,
Russo et al. 2012).
The aim of this study was to determine the prevalence
and spectrum of the NIPBL gene point mutations among
Polish CdLS patients diagnosed in the period 2006–2011.
More to the point, patients negative for point mutations were
subjected to further evaluation aimed at the identification of
large genomic rearrangements (deletion/duplication of
exons) within the NIPBL gene. The additional objective of
the study was to compare the spectrum of mutations identi-
fied so far in Polish patients (Yan et al. 2006; Ratajska et al.
2010; Wierzba et al. 2011 and current results) with muta-
tions described in CdLS patients from other populations.
Materials and methods
Sixty-four unrelated patients (34 females and 30 males) with
clinical diagnosis of CdLS referred for genetic screening of
the NIPBL gene between 2006 and 2011 through the Polish
Cornelia de Lange Association were evaluated in the study.
In accordance with the diagnostic criteria for CdLS (Kline et
al. 2007), 31 (48 %) patients were classified as having
classical (severe) phenotype and 33 (52 %) as having the
mild form of CdLS.
DNA and, in selected cases, also RNA, was extracted
from peripheral blood samples (Genomic Midi AX kit; Total
RNA Mini kit; A&A Biotechnology). The complete coding
sequence of the NIPBL gene, including splice junctions, was
evaluated by a combination of the denaturing high-
performance liquid chromatography (DHPLC) technique
(WAVE DNA Fragment Analysis System, Transgenomic
Inc.) and bi-directional sequencing (Applied Biosystems).
All novel variants were verified in the dbSNP, the 1000
Genomes catalogue and the NHLBI Exome Sequencing
Project. Whenever available, de novo origin of the muta-
tions was verified through parents’ testing. Besides, selected
bioinformatics resources, including UCSC Genome Bioin-
formatics and UniProtKB tools, along with PolyPhen-2 and
SIFT web interfaces, were used to assess the effect of the
detected novel sequence variants on the structure and func-
tion of the protein. Potential effects on the splicing process
were explored both in silico (Human Splicing Finder and ESE-
finder web interfaces) and by reverse transcription polymerase
chain reaction (RT-PCR) studies (Bioscript; Bioline Inc.).
Thirty-nine (39, 61 %) CdLS patients found to be nega-
tive for NIPBL point mutations were subjected to extended
screening for genomic rearrangements using a Multiplex
Ligation-dependent Probe Amplification (MLPA) and
array-comparative genomic hybridization (aCGH) ap-
proach. PCR fragments from MLPA reactions performed
using commercial kits P141 and P142 (MRC Holland) were
analysed on an ABI PRISM 310 Genetic Analyzer (Applied
Biosystems) using TAMRA-500 (Applied Biosystems) as
the size standard. Raw data of each individual exon peak
area were transferred to an Excel spreadsheet (Microsoft).
Probe ratios below 0.7 were regarded as exons deletion and
probe ratios above 1.3 as duplication. All abnormal results
were repeated in a second independent experiment and,
where confirmed, aCGH analysis of the given sample was
performed using the Human Genome CGH Microarray
105A kit (Agilent Technologies). As the reference, DNA
isolated from peripheral blood leukocytes of nine anony-
mous healthy females was used. The arrays were scanned
with the Axon GenePix 4000B scanner and GenePix Pro 6.0
software (Molecular Devices); the results were analysed
using Feature Extraction 9.5.3 software (Agilent Technolo-
gies). All procedures were performed according to the
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manufacturers’ instructions. More information on screening
protocols, including the choice of primers, can be obtained
from the corresponding author upon request.
Written informed consent was obtained from the relevant
guardians of the children and from patients themselves,
whenever eligible. The study was approved by the Ethical
Committee of the Medical University of Gdansk, Poland
(NKEBN/380/2006).
Results
Twenty-two (22, 34 %) patients were found to have novel
private NIPBL sequence variants located along the entire cod-
ing sequence of the gene (Table 1). Besides, three previously
described point mutations were detected in the analysed cohort
of CdLS patients. The most common were non-synonymous
sequence variants (n015), followed by deletions (n07), splice-
site intronic mutations (n02) and a duplication (n01).
The 15 identified missense sequence variants, including
two previously described mutations, were located along the
entire coding sequence. The two known mutations were
c.6892C>T and c.4321G>T (Table 1). In order to assess
the pathogenic significance of the detected novel non-
synonymous variants, in-silico structure–function analyses
were attempted in all cases. BLAST search of the Protein
Data Bank (http://www.pdb.org, 20.09.2012) with delangin
sequence revealed no solved structures of proteins with
considerable sequence similarity, except for the HEAT and
PxVxL motifs. Seven substitutions affected evolutionarily
conserved amino acid residues; however, none of them lay
within five HEAT repeat domains, the crucial and highly
conserved C-terminal portion of the protein.
Truncating mutations were the second most common
type of mutations (n08). This subgroup included seven
deletions and one duplication, all leading to reading frame
shift, resulting in premature protein truncation. It should be
underlined that all truncating mutations occurred in patients
with classic type of the disease.
Three splice-site mutations, including the above pre-
sented exonic missense c.4321G>T and two novel intronic
variants, were also detected. To confirm the pathogenic
character of the novel variants, in-silico studies were per-
formed. Moreover, in the case of c.3855+1delG, biological
samples for RNA studies were also available. cDNA analysis
confirmed that c.3855+1delG leads to exon 16 skipping. Even
though there was no possibility to obtain blood samples for
RNA analysis from the patient with the c.5863-1G>C variant,
the position of this alteration strongly suggests its impact on
the splicing process and a highly probable deletion of exon 33,
as predicted by in-silico tools.
Patients with no NIPBL sequence alteration detected on
direct sequencing were eligible for extended screening. No
segmental indels within the gene were detected, while in
two cases, MLPA analysis showed reduction of probe ratios
below 0.6 for all exons, suggesting deletion of the entire
NIPBL gene. The exact size and type of genomic alteration
was further evaluated by aCGH. Both patients were found to
have sub-microscopic interstitial deletions on the short arm
of chromosome 5. The larger of the two deletions, of
approximately 1.7 Mb, encompassed not only the entire
NIPBL sequence, but also five other genes (namely,
SLC1A3, FLJ1323, NUP155, WDR70, GDNF). The second
patient was found to carry a deletion of about 0.65 Mb in
size. In this case, a deleted region included NIPBL,
FLJ1323, NUP155 and a part of the WDR70 gene.
Discussion
NIPBL gene mutations are the most common cause of CdLS
worldwide, estimated to account for ca. 50 % of cases
(Oliveira et al. 2010). The remaining patients have altera-
tions in SMC1A (ca. 5 %), SMC3 (<1 %) and the recently
discovered RAD21 and HDAC8 (Deardorff et al. 2007,
2012a, b). So far, the prevalence of mutations in the
RAD21 and HDAC8 genes is rather anecdotal and large
population studies are needed in order to evaluate their signif-
icance in the clinical setting (Deardorff et al. 2012a, b). Then
again, a number of candidate genes (STAG2, ESCO1, ESCO2,
PDS5 and MAU2) are subject to intensive studies aimed at
proving their pathogenicity in humans, but no clinically rele-
vant reports have been published so far.
Against this background, it should be underlined, how-
ever, that, despite the fact that several genes are indicated to
be involved in CdLS, with NIPBL playing first fiddle, so far,
in more than half of the patients, no genetic cause has been
identified. At the current state of knowledge, while waiting
for next-generation sequencing techniques to enter clinical
practice, the optimal diagnostic screening strategy should
include, in the first place, testing of the entire coding se-
quence of NIPBL, and only later referring the patient to
more extended screening in line with the severity of the
presented phenotype.
In the current study, the mutation detection yield of 42 %
was similar to the mean value observed in the previously
published reports, although the mutation detection rate dif-
fers considerably between published studies, ranging from
26 to 70 % (Borck et al. 2004; Gillis et al. 2004; Miyake et
al. 2005; Yan et al. 2006; Bhuiyan et al. 2006; Schoumans et
al. 2007; Selicorni et al. 2007; Kline et al. 2007; Pié et al.
2010). The observed discrepancies between the studies
could result from the size of the group, accuracy of clinical
diagnosis, selection of patients for the study or even differ-
ences in methods used for molecular analysis. Nevertheless,
taking together all the results obtained so far from NIPBL
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Table 1 NIPBL gene alterations identified in Polish patients with Cornelia de Lange syndrome. All mutations detected in the current analysis as
well as mutations identified in previous studies (Yan et al. 2006; Ratajska et al. 2010; Wierzba et al. 2011) are shown
Exon
(intron)
Nucleotide change Effect Status Origin Phenotype
A. Sequence variants identified in the exonic sequences
3 c.209A>T p.Asn70Ile This study (novel) Unknown Classic
4 c.269delG p.Gly90Valfs*31 This study (novel) Unknown Classic
5 c.415_416insTTAT p.Ser139Phefs*13 Yan et al. (2006) De novo Classic
6 c.535G>T p.Ala179Ser This study (novel) De novo Mild
7 c.737A>G p.Asp246Gly Yan et al. (2006) [previously reported in the
NIPBL mutation database (Oliveira et al.
2010) in a German patient]
De novo Classic
9 c.1012_1016delCAGAG p.Gln338* This study (novel) Unknown Classic
9 c.1051C>A p.Pro351Ser This study (novel) De novo Mild
9 c.1071A>C p.Lys357Asn This study (novel) De novo Classic
10 c.2296delA p.Arg766Glyfs*27 This study (novel) Unknown Classic
10 c.2322_2323delGA p.Lys776Thrfs*2 Yan et al. (2006) De novo Classic
10 c.2485_2486dupTG p.Glu829Valfs*19 This study (novel) Unknown Classic
10 c.2603G>A p.Arg868Gln This study (novel) De novo Classic
10 c.2920_2921delAA p.Lys974Glufs*19 Yan et al. (2006) De novo Classic
10 c.3060_3063delAGAG p.Glu1021Thrfs*22 This study (previously reported by Gillis et al.
2004; unknown ethnicity, and by Bhuiyan
et al. 2006; Dutch patient)
Unknown Classic
13 c.3525dupA p.Glu1176Argfs*10 Yan et al. (2006) De novo Classic
14 c.3619G>A p.Glu1207Lys This study (novel) De novo Classic
17 c.4015T>C p.Tyr1339His This study (novel) Unknown Mild
19 c.4306A>C p.Lys1436Gln This study (novel) Unknown Classic
20 c.4321G>T p.(Phe1442Lysfs*3,
Val1441Leu)
This study (previously reported by Pé et al.
2010 in a Spanish patient)
De novo Mild
21 c.4450delC p.Pro1484Serfs*137 This study (novel) Unknown Classic
24 c.4873G>T p.Val1625Phe This study (novel) Unknown Mild
24 c.4909A>C p.Ile1637Leu This study (novel) De novo Mild
26 c.5167C>T p.Arg1723* Yan et al. (2006) (previously reported by Gillis
et al. 2004 in two patients)
De novo Classic
26 c.5164A>C p.Asn1722His This study (novel) De novo Classic
26 c.5207_5222del16 p.Ser1736* This study (novel) Unknown Classic
37 c.6409_6412delAAAC p.Lys2137Glnfs*33 This study (novel) Unknown Classic
37 c.6475G>T p.Glu2159* Yan et al. (2006) Unknown Classic
39 c.6653_6655delATA p.Asn2218del Yan et al. (2006) [previously reported by Borck
et al. 2004 in a French patient; and in the
NIPBL mutation database (Oliveira et al.
2010)
in a Portuguese patient]
De novo Classic
40 c.6873dupT p.His2292Serfs*48 Yan et al. (2006) De novo Classic
40 c.6892C>T p.Arg2298Cys This study (previously reported by Gillis et al.
2004; unknown ethnicity, also by Selicorni et
al. 2007 in a Italian patient and Kline et al.
2007 in a Swedish patient)
De novo Classic
40 c.6935G>T p.Gly2312Val This study (novel) De novo Classic
42 c.7096C>T p.Gln2366* Yan et al. (2006) De novo Classic
43 c.7297G>A p.Asp2433Asn This study (novel) Unknown Classic
44 c.7439_7440delGA p.Arg2480Lysfs*5 Yan et al. (2006) (reported by Pié et al. 2010 in
a Spanish patient)
De novo Classic
44 c.7559delA p.Asn2520Ilefs*3 Yan et al. (2006) De novo Classic
46 c.7950dupT p.Thr2651Tyrfs*10 Yan et al. (2006) De novo Classic
B. Sequence variants identified in the intronic sequences
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testing in Polish patients (Table 1), the mutation detection
rate remains relatively high (45 %) in the Polish population,
providing further evidence of the clinical significance of
NIPBL testing in all CdLS patients. Furthermore, we have
found that 61 % of patients with severe phenotype and 24 %
of children with mild form of the disease were positive for a
mutation in the NIPBL gene. Taken together all the results
obtained so far in the Polish cohort of patients, 64 % of
classic CdLS cases and merely 20 % of mild ones had
deleterious NIPBL alteration. Our findings are in line with
the previously published reports, which point out the sever-
ity of NIPBL-associated CdLS phenotype, as shown by
much higher mutation detection rates for this gene observed
among severely affected children. More to the point, large
genomic rearrangements encompassing the NIPBL locus
were previously reported only in patients with classic form
of the disease. This is also the case with respect to the
current study, and to the Polish cohort in general, as we
have detected interstitial deletions at chromosome 5p13.2 in
3 % of patients, all with the utmost severe phenotype.
Mutational analysis of the entire coding sequence of the
NIPBL gene in the Polish cohort, both analyzed in the current
study and analyzed together with the previous reports, con-
firmed that there is no evident hot spot. All identified muta-
tions were private, except for seven (Table 1). For instance,
our study is the first to report mutations in exon 24 of the gene.
Our findings prove to be consistent with previous studies, as,
so far, the most common mutation in CdLS patients, namely,
p.Arg827Glyfs*2, was reported in seven (2 %) patients only
(Oliveira et al. 2010). With regard to the seven recurrent
mutations that were present both in a Polish patient and in
previously reported patients from other ethnic and/or geo-
graphical origin, only in four (c.3060_3063delAGAG;
c.4321G>T; c.5167C>T; c.7439_7440delGA) was the clini-
cal picture of the disease similar to the phenotype presented by
our patients (Gillis et al. 2004; Bhuiyan et al. 2006; Pié et al.
2010) . Converse ly, c .737A >G, c.6892C > T and
c.6653_6655delATA have been identified in patients with
varying phenotypes (Gillis et al. 2004; Borck et al. 2004;
Selicorni et al. 2007; Kline et al. 2007). This suggests that, in
the case of CdLS, the same genetic change does not always
lead to the same degree of disease severity, a phenomenon
which is probably influenced by additional, not yet specified,
modifying factors (Gillis et al. 2004; Pié et al. 2010).
Over 250 variousNIPBL point mutations have already been
described in CdLS patients, the most common being missense
mutations (28 %) and deletions leading to frame shift (23 %),
followed by nonsense and split-site mutations (each 18 %),
while less frequent variants are insertions and complex indels
(Oliveira et al. 2010). Mutations detected in Polish patients
follow a similar pattern with respect to the type and frequency
of each of the categories. More to the point, the analysis of the
subgroups of the patients distinguished with respect to the
severity of the phenotype into classic and mild shows that
truncating mutations and large genomic rearrangements oc-
curred exclusively in the severe cases, while missense and
splice-site mutations were observed in both groups of the
patients. These results are in accordance with the literature data
(Tonkin et al. 2004; Gillis et al. 2004; Schoumans et al. 2007;
Pié et al. 2010; Oliveira et al. 2010).
In order to assess the pathogenic effect of the detected
novel missense variants, a number of bioinformatical analy-
ses has been performed. Instead of experimental verification
of the potential presence of the detected variants in the
control group of healthy volunteers, we have decided to
check their incidence in two large exome sequence variant
databases (1000 Genomes, NHLBI). Only one of the alter-
ations present in our CdLS patients, namely, c.2603G>A,
was found among benign variants (rs149629686) reported in
these databases, with the frequency of the minor allele
(MAF) being 0.04 %. Besides, c.535G>T affected the same
nucleotide as a rare polymorphism c.535G>A reported in
databases (rs142923613; MAF 0.2 %) but resulted in a
different residue substitution (serine and not threonine). Six
out of eight variants detected in the CdLS patients presenting




Nucleotide change Effect Status Origin Phenotype
16 c.3855+1delG p.Leu1257_His1285del This study (novel) Unknown Mild
29 c.5575-2delA p.Asp1859_Lys1903del Wierzba et al. (2011) De novo Classic
32 c.5863-1G>C p.Leu1955_Ala1990del This study (novel) De novo Mild
C. Large genomic rearrangements
35–47 63 kb deletion, breakpoints: 37,076,861–37,139,520a Ratajska et al. (2010) Unknown Classic
Whole gene 1.7 Mb deletion, breakpoints: 36,487,985–38,154,159a This study (novel) Unknown Classic
Whole gene 0.65 Mb deletion, breakpoints: 36,771,925–37,427,989a This study (novel) Unknown Classic
a Chromosomal coordinates are given according to the NCBI36/hg18 assembly
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PolyPhen-2 algorithms to be deleterious and were found to
affect evolutionary conserved residues. The two exceptions
were c.2603G>A and c.5164A>C alterations. C.2603G>A
was eventually called a mild variant, because not only was it
found to be present in a 6/23,761 healthy individuals collected
in the analysed exome databases, but also it affects a non-
conserved residue in a non-structuralised fragment of the
protein. Likewise, c.5164A>C affects a non-conserved resi-
due and the analysis of the alignment reveals that at least five
distinct amino acids with different physical characteristics
occur at this site in various species. Nevertheless, both were
de novomutations, hence, we cannot explicitly decide on their
pathogenic effect. Then again, five novel missense variants
were reported in patients with mild form of CdLS. All but
c.4873G>T, which affects a evolutionary conserved amino-
acid residue, were classified as benign by the online in-silico
tools; however, as no precise structural evaluation, due to the
lack of solved structures of proteins with considerable se-
quence similarity, could be performed, it cannot be excluded
that their presence is responsible for the mild phenotype
observed in the patients. In the case of c.4909A>C, the
replaced amino acid has similar physical characteristics, thus,
the probability of its influence on the protein structure is rather
low. Accordingly, these variants were categorized as mild,
even though they were confirmed to be de novo.
Although CdLS is a monogenic disease, there have been
over 30 cases of chromosomal abnormalities associated with
that syndrome (DeScipio et al. 2005). In fact, a de novo
balanced translocation involving chromosome 5 facilitated
identification of the NIPBL gene (Tonkin et al. 2004). Recent-
ly, a few reports have been published presenting several cases
with sub-microscopic deletions encompassing the NIPBL
gene, with the size of aberration ranging from 4.2 kb (a single
exon) to 2Mb deletion, including not only theNIPBL gene but
also 14 adjacent genes (Bhuiyan et al. 2007; Ratajska et al.
2010; Oliver et al. 2010, Murray et al. 2012; Pehlivan et al.
2012; Russo et al. 2012). The incidence of genomic aberra-
tions was estimated to be 4–5 % of CdLS patients negative for
the NIPBL point mutation (Pehlivan et al. 2012; Russo et al.
2012). Likewise, in the current study, we have detected two
genomic alterations in the group of 39 Polish patients negative
for point mutations in NIPBL (i.e. 5 %). Yet, the detection rate
for the entire cohort of patients was <3 %, showing that, by
and large, NIPBL alterations present in CdLS patients are
point mutations. Both deletions occurred in patients with the
most severe phenotype; however, no significant clinical fea-
ture atypical for CdLS was observed in these children.
Conclusions
In the current study, we have performed a comprehensive
analysis of NIPBL alterations in a Polish cohort of Cornelia
de Lange syndrome (CdLS) patients. Similarly to other
populations and ethnic groups, no founder effect or hot spot
within the gene were observed, as the prevailing type of
mutations were novel private ones. In addition, we have
confirmed the presence of large genomic rearrangements
in the portion of the most severely affected patients; how-
ever, the detection rate of ∼5 % disqualifies the test from
wide usage in clinical settings. We anticipate however, that
the introduction of new diagnostic tools, next-generation
sequencing in particular, which is at the point of entering
clinical practice, will soon allow testing of all the postulated
candidate genes involved in proper cohesion complex activ-
ity in the to-date undiagnosed portion of patients with re-
spect to point mutations and to gene(s) dosage.
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